22 June 2010 - For the very first time, a medicine has been shown to protect against the development of Alzheimer’s disease. French scientists were able to demonstrate that taking 240 mg of Ginkgo extract EGb 761® per day regularly over a period of at least 4 years can cut the risk of developing Alzheimer’s disease by nearly 50%.
“The results of the GuidAge study are remarkable”, according to Prof. Michael Habs, Managing Director at Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, producers of EGb 761® (Tebonin®, pharmacy only). “It is the first time ever that a protective effect against Alzheimer’s disease has been demonstrated for a medicine. The multifaceted effects of the plant extract appear to positively influence the complex developmental processes of dementia.”
The GuidAge study was a large-scale study, in which 2854 elderly people with memory complaints were randomly assigned to receive either 240 mg/day of the patented Ginkgo special extract or a placebo for five years... Dr. Willmar Schwabe Pharmaceuticals' Press Release -
Blog Archive
-
▼
2010
(50)
-
▼
July
(7)
- Amorfix : New Insights Into Alzheimer's Disease Pr...
- Plexxikon : Novel Agent Significantly Inhibits Act...
- Schwabe Pharmaceuticals : Major study shows that l...
- Watson Pharmaceuticals : Generic Exelon
- GTX Corp and Aetrex Worldwide, Inc. : Licensing Ag...
- Vermillion : Issuance of Patent for Alzheimer's D...
- Intellect Neurosciences : Notice of Allowance for ...
-
▼
July
(7)